# COVID-19 Vaccine Efficacy in patients with Blood Cancer

ACTRN12621000538842

| | |
|---|---|
| **Status** | RECRUITING |
| **Sponsor** | Royal Brisbane and Women's Hospital |
| **Enrollment** | 50 participants |

## Plain Language Summary

People with blood cancers such as lymphoma, myeloma, and leukaemia are often treated with therapies that specifically target B cells — a type of immune cell that is central to producing antibodies. This means that after vaccination (including COVID-19 vaccines), their immune systems may not respond as strongly as those of healthy people. This study investigates exactly how much protection COVID-19 vaccination provides to these patients.

You may be eligible for the blood cancer group (Cohort A) if you are 18 or older, have a blood cancer diagnosis (including non-Hodgkin's lymphoma, myeloma, Hodgkin's lymphoma, or leukaemia), have received B-cell targeted therapy or a bone marrow transplant, and are planning to receive a COVID-19 vaccine. Healthy adults without cancer or immune-depleting treatments are also being recruited to a comparison group (Cohort B).

Participants provide up to five blood samples — before the first dose and up to 6 months after the second dose — so researchers can measure how well the immune system responds over time. This information is vital for guiding vaccination policy and booster recommendations for people with blood cancers.

## Key Eligibility Criteria

### Inclusion (5)

- Greater than or equal to 18 years of age
- Able to provide voluntary informed consent
- Planned receipt of a COVID19 vaccine of any variety; e.g. Pfizer-BioNTech BNT162b2, AstraZeneca Oxford ChAdOx1 nCoV-19 (AZD1222), Novavax NVX-CoV2373 or ModernaTX mRNA-1273 vaccine.
- Patients who have any haematological malignancy and received treatment with a B-cell targeted therapy or who have received a bone marrow transplant may be recruited to Cohort A.
- Patients who do not have a diagnosis of a haematological malignancy or any other active cancer, and who have not received treatment with B cell depleting antibodies will be recruited to Cohort B. 50 patients will be recruited in total, 30 to Cohort A and 20 to Cohort B.

### Exclusion (3)

- Current diagnosis of and/or treatment for a non-haematological malignancy.
- Receipt of B cell targeted therapies for Rheumatological or other non-haematological malignancy indication
- Unable to provide voluntary informed consent

## Locations (1 total)

Royal Brisbane & Womens Hospital - Herston, QLD, Australia